Australia’s Pharmako Biotechnologies is launching its first liposomal technology which could be used to increase the bioavailability of nutraceuticals containing nutrients that are hydrophilic and lipophilic in nature.
Gencor Pacific is eyeing new product development opportunities aimed at improving the quality of life in individuals who experience the lingering effects of COVID-19 infection, following new trial findings on one of its trademarked ingredients.
Palmitoylethanolamide (PEA) has shown to inhibit the COVID-19 virus in both in-silico and in-vitro settings, and positive findings from a clinical trial are expected to be published in Q3, says functional ingredient firm Gencor.
An ingredient commonly isolated from soybeans, peanuts, and egg yolks, has been shown in a recent review to act in similar pathways as cannabidiol (CBD), with researchers highlighting that it was a safer and legally recognised alternative.
Gencor is venturing into the hair care oral supplement and topical application category, with an RCT studying the benefits of ageratum conyzoides oral supplementation and topical application to take place this year.
An increasingly stricter regulatory framework and surging demand for safer products from both elite sportsmen and everyday consumers is driving the appeal of professionally accredited sports nutrition ingredients, not only finished products.
Drinking a high bioavailability curcumin formulation before and after exercise could speed up recovery, allowing athletes to resume training quicker and exercise at higher thresholds, says a new study funded by Gencor Pacific.